



SERENDEX

Pharmaceuticals

ERS 2015 • EVENING EXPERT FORUM, TUESDAY 29 SEPTEMBER 2015 • 17.30 - 19.00

# **PULMONARY ALVEOLAR PROTEINOSIS AND SEVERE PULMONARY INFECTIONS - ROLE OF IMMUNE MODULATORS (FOCUS ON GM-CSF)**

Chairman: Prof. Dr. U. Costabel, Co-Chairman: Prof. Dr. Y. Inoue • Venue: Room E107, Amsterdam RAI, Netherlands

## **PROGRAM**

**17.30-17.35 INTRODUCTION**

Speaker: Prof. U. Costabel, Essen, Germany

**17.35-17.55 PAP EPIDEMIOLOGY AND CLASSIFICATION**

Speaker: Prof. Y. Inoue, Osaka, Japan

**17.55-18.10 PAP PATHOGENESIS**

Speaker: Dr. F. Bonella, Essen, Germany

**18.10-18.30 PAP TREATMENT AND ADVANCES IN THERAPY**

Speaker: Prof. U. Costabel, Essen, Germany

**18.30-18.55 SEVERE PULMONARY INFECTIONS - ROLE OF GM-CSF/  
IMMUNE MODULATORS**

Speaker: Dr. Herold, Giessen, Germany

**18.55-19.00 GENERAL DISCUSSION AND SUMMARY**

Speaker: Prof. Y. Inoue, Osaka, Japan

# ABOUT THE SPEAKERS

## PROF. COSTABEL:

Dr. Ulrich Costabel is Senior Consultant and Head of Clinical Research of the Interstitial and Rare Lung Disease Unit at the Ruhrlandklinik in Essen, Germany. Research interests: Translational studies with a specific focus on the application of bronchoalveolar lavage in interstitial lung diseases (ILDs). He is Principal Investigator in the most important clinical trials on IPF, past Chief editor of ERJ, and author of more than 300 scientific papers and chapters.

## DR. BONELLA:

Dr. Francesco Bonella is Senior Clinical Researcher at the Interstitial and Rare Lung Disease Unit of the Ruhrlandklinik in Essen, Germany. Research interests: Clinical and immunological studies in ILDs, with a specific

focus on biomarker research in rare lung diseases. Author of several scientific papers and chapters. Dr. Bonella is founder of EuPAPNet, a European network for Pulmonary Alveolar Proteinosis and Secretary of the ERS diffuse parenchymal lung disease group.

## PROF. INOUE

Dr. Med. Yoshikazu Inoue is Executive Director of the Clinical Research Center at the National Hospital Organization Kinki-Chuo Chest Medical Center in Osaka Japan, and Invited Professor of the Graduate School of Medicine, Osaka University. His institute is one of the leading hospitals and research centers for chest diseases, and an important referral center for ILDs. He has served as Principal Investigator and board member of many international and domestic statements,

and guidelines. Prof. Inoue is author of numerous scientific papers with focus on clinical and basic research on ILD including pulmonary alveolar proteinosis, lymphangioleiomyomatosis, idiopathic pulmonary fibrosis and other interstitial pneumonias.

## DR. HEROLD

PD Dr. Med. Susanne Herold is Consultant of Internal Medicine and Infectious Diseases Department, University of Giessen and Marburg Lung Center, Germany. Research interests: Infectious lung diseases, acute lung injury/acute respiratory distress syndrome. Associate editor of Am J Resp Cell Mol Biol, Adjunct Professor of Northwestern University of Chicago, and author of numerous scientific papers and chapters.

## ABOUT SERENDEX PHARMACEUTICALS A/S

Serendex develops drugs to treat severe respiratory conditions such as PAP (pulmonary alveolar proteinosis), ARDS (acute respiratory distress syndrome), BE (bronchiectasis), CF (cystic fibrosis related lung infections) and DAH (diffuse alveolar hemorrhage). These conditions are acute or chronic and have no existing medical treatment. All Serendex drugs are inhaled or induced to the lungs of the patient. This improves the risk/efficacy ratio of the drug and treatment. Serendex has obtained orphan drug designation (ODD) for several indications in both Europe and USA. The company's sole business focus is drug repositioning, i.e. finding new indications and administration routes for existing drugs. Serendex Pharmaceuticals is listed at Oslo Axess. Please visit [www.serendex.com](http://www.serendex.com) to learn more.